Patents Assigned to CELLABMED INC.
  • ANTIBODY SPECIFICALLY BINDING TO B7-H3
    Publication number: 20260201038
    Abstract: The present disclosure relates to an anti-B7-H3 antibody or an antigen-binding fragment thereof, which binds to a specific epitope located within the amino acid sequence of a domain of B7-H3. The antibody (i) specifically binds to various types of cancer cell lines expressing B7-H3, demonstrating T cell-mediated cancer cell-killing effect, and (ii) binds to epitopes in both humans and mice, thus allowing for effective evaluation of anticancer effect in preclinical trials when developed into a therapeutic antibody.
    Type: Application
    Filed: November 15, 2023
    Publication date: July 16, 2026
    Applicant: CELLABMED INC.
    Inventors: Anna JU, Min-Gu KIM, Boram LEE, Sangeun LEE, Yeongha JEON, Song-Jae LEE, Seong-Won SONG, Ji Chul LEE, Sung-Won MIN, Won Hye KA, Hyeong Sun KWON, Kyung Hee RHEE, Gong-Deuk BAE, Nam Hyuk KIM, Jineui LEE
  • Chimeric antigen receptors, and T cells in which chimeric antigen receptor is expressed
    Patent number: 10975148
    Abstract: Disclosed is a chimeric antigen receptor comprising an antigen binding domain; a hinge region; a transmembrane domain; a costimulatory domain; and a cytoplasmic signaling domain.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: April 13, 2021
    Assignee: CELLABMED INC.
    Inventor: Seogkyoung Kong